Literature DB >> 24670705

Value of procalcitonin in differentiating pulmonary tuberculosis from other pulmonary infections: a meta-analysis.

S-L Huang1, H-C Lee2, C-W Yu3, H-C Chen3, C-C Wang1, J-Y Wu4, C-C Lee5.   

Abstract

OBJECTIVES: To systematically and quantitatively summarise the current evidence on the utility of the procalcitonin test (PCT) in discriminating pulmonary tuberculosis (TB) from other pulmonary infections.
METHODS: We searched MEDLINE, EMBASE and the Cochrane database up to August 2013 for studies that reported the performance of PCT alone or compared with other biomarkers in diagnosing pulmonary TB. We summarised PCT using forest plots, hierarchical summary receiver operating characteristic curves and bivariate random effects models.
RESULTS: We found nine qualifying studies covering 951 episodes of suspected TB along with 426 confirmed TB cases. The bivariate pooled sensitivity and specificity of PCT to distinguish TB from non-TB were respectively 42% (95%CI 30-56) and 87% (95%CI 63-96). The bivariate pooled sensitivity and specificity for PCT in distinguishing TB from bacterial pneumonia were respectively 78% (95%CI 67-86) and 85% (95%CI 78-90). Low heterogeneity was noted in studies comparing TB with bacterial pneumonia patients.
CONCLUSION: The results suggest consistently acceptable sensitivity and specificity of the PCT test in distinguishing TB from bacterial pneumonia. However, given the imperfect sensitivity and specificity of the test, medical decisions should be based on both the PCT test results as well as on clinical findings.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24670705     DOI: 10.5588/ijtld.13.0449

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  7 in total

1.  Extensive Radiological Manifestation in Patients with Diabetes and Pulmonary Tuberculosis: A Cross-Sectional Study.

Authors:  Senlin Zhan; Xiong Juan; Tantan Ren; Yuxiang Wang; Liang Fu; Guofang Deng; Peize Zhang
Journal:  Ther Clin Risk Manag       Date:  2022-05-23       Impact factor: 2.755

2.  Use of procalcitonin in the diagnosis of tuberculosis in infants and preschool children.

Authors:  Eneritz Velasco-Arnaiz; Esther Pérez; Desirée Henares; Anna Fernández-López; Anna Valls; Pedro Brotons; Clàudia Fortuny; Antoni Noguera-Julian
Journal:  Eur J Pediatr       Date:  2018-01-27       Impact factor: 3.183

3.  Procalcitonin as a Diagnostic and Prognostic Factor for Tuberculosis Meningitis.

Authors:  Jinseung Kim; Si Eun Kim; Bong Soo Park; Kyong Jin Shin; Sam Yeol Ha; Jinse Park; Sung Eun Kim; Kang Min Park
Journal:  J Clin Neurol       Date:  2016-05-10       Impact factor: 3.077

4.  Risk factors for extrapulmonary dissemination of tuberculosis and associated mortality during treatment for extrapulmonary tuberculosis.

Authors:  Xu Qian; Duc T Nguyen; Jianxin Lyu; Andreas E Albers; Xiaohong Bi; Edward A Graviss
Journal:  Emerg Microbes Infect       Date:  2018-06-06       Impact factor: 7.163

5.  Pneumonia caused by Mycobacterium tuberculosis.

Authors:  Meili Wei; Jun Xi; Jun Wei; Bikui Tang
Journal:  Microbes Infect       Date:  2020-06-16       Impact factor: 2.700

6.  The Sustained and Marked Elevation of Serum Procalcitonin in a Hemodialysis Patient with Tuberculous Lymphadenitis, but Without the Evidence of Sepsis: A Case Report.

Authors:  Peiyi Luo; Yanqiong Long; Liang Ma; Ye Tao; Shenju Gou
Journal:  Infect Drug Resist       Date:  2022-09-02       Impact factor: 4.177

Review 7.  Transformative tools for tackling tuberculosis.

Authors:  Jennifer L Gardiner; Christopher L Karp
Journal:  J Exp Med       Date:  2015-10-12       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.